CALL/FRESENIUS MEDICAL CARE/30/0.1/21.06.24 Share Price

Warrant

DE000GK9NX73

Market Closed - BOERSE MUENCHEN 11:55:52 14/06/2024 pm IST
0.87 EUR -2.25% Intraday chart for CALL/FRESENIUS MEDICAL CARE/30/0.1/21.06.24
Current month-6.45%
1 month-21.62%
Date Price Change
14/24/14 0.87 -2.25%
13/24/13 0.89 -11.88%
12/24/12 1.01 +5.21%
11/24/11 0.96 -2.04%
10/24/10 0.98 -0.41%

Real-time BOERSE MUENCHEN

Last update June 14, 2024 at 11:55 pm IST

More quotes

Static data

Product typePlain-Vanilla-Warrants
Buy / SellCALL
Underlying FRESENIUS MEDICAL CARE AG
Issuer Goldman Sachs
WKN GK9NX7
ISINDE000GK9NX73
Date issued 26/08/2022
Strike 30
Maturity 21/06/2024 (6 Days)
Parity 10 : 1
Emission price 0.84
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 2.12
Lowest since issue 0.421
Spread 0.05
Spread %5.49%

Company Profile

Fresenius Medical Care AG, formerly Fresenius Medical Care AG & Co. KGaA is a Germany-based Company, which is a kidney dialysis institute. The Company provides dialysis care and related services to persons suffering from end-stage renal disease (ESRD), as well as other healthcare services. The Company also develops and manufactures a wide variety of health care products, which includes dialysis and non-dialysis products. Its dialysis products include hemodialysis machines, peritoneal cyclers, dialyzers, peritoneal solutions and granulates, bloodlines, renal pharmaceuticals and systems for water treatment. Its non-dialysis products include acute cardiopulmonary and apheresis products. The Company supplies dialysis clinics it owns, operates or manages with a broad range of products, and sells dialysis products to other dialysis service providers.
Sector
-
More about the company

Ratings for Fresenius Medical Care AG

Trading Rating
Investor Rating
ESG Refinitiv
A-
More Ratings

Consensus: Fresenius Medical Care AG

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
19
Last Close Price
38.63 EUR
Average target price
39.97 EUR
Spread / Average Target
+3.48%
Consensus